Compare J B Hunt Transport Services Inc (JBHT) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance

J B Hunt Transport Services IncTrade

Recursion Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

J B Hunt Transport Services Inc vs Recursion Pharmaceuticals Inc — how do they compare? J B Hunt Transport Services Inc trades at $292.56 (market cap $27.36B), while Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B). The key difference: J B Hunt Transport Services Inc is far larger — about 17.9× Recursion Pharmaceuticals Inc's market cap, and J B Hunt Transport Services Inc pays a 0.62% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

	JBHT	RXRX
Market Cap	$27.36B	$1.53B
Sector	Industrials	Health
52-Week High	$298.41	$6.79
52-Week Low	$130.65	$2.84
Enterprise Value	$28.50B	$946.50M
Dividend Yield	0.62%	—

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

JBHT

Equal-weight S&P 500 ETF outperforms cap-weighted peers, driven by semiconductors and yield curve shifts.24/7 Wall Street · 3 days agoBullish J.B. Hunt reports strong Q2 2026 profit growth led by intermodal volume gains, but valuation limits upside.Seeking Alpha · 4 days agoNeutral View details →

RXRX

View details →

About J B Hunt Transport Services Inc

J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (45% of sales in 2021).

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.